“`html
AbbVie Inc. (ABBV) has expanded its oncology offerings, now including drugs like Epkinly for lymphoma, Elahere for ovarian cancer, and Emrelis for lung cancer. As of the first nine months of 2025, oncology sales accounted for over 11% of AbbVie’s total revenues, which grew 3% year over year.
The company has plans to strengthen its portfolio with antibody-drug conjugates (ADCs), including a regulatory filing under FDA review for pivekimab sunirine, targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN). If approved, this will be AbbVie’s third ADC. Additionally, AbbVie is conducting late-stage studies for etentamig/ABBV-383 in relapsed/refractory multiple myeloma.
Competitors in the oncology space include AstraZeneca, Merck, and Pfizer. AstraZeneca’s oncology sales comprise 43% of total revenues, reflecting a 16% increase year over year. Merck’s Keytruda accounts for about 48% of its total revenues, while Pfizer’s oncology segment grew 7%, now accounting for over 27% of its total revenues.
“`
